Circulation Research, Vol 73, 503-513, Copyright © 1993 by American Heart Association

ARTICLES

Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise. A role for adenosine

JD Symons, E Firoozmand and JC Longhurst
Department of Internal Medicine, University of California, Davis 95616.

Two main hypotheses concerning the mechanisms responsible for coronary collateral growth suggest the involvement of chemical or mechanical factors. Since we recently demonstrated that the development of the coronary collateral circulation is not closely related to the extent or duration of myocardial ischemia, we hypothesized that chronic repeated vasodilation and increased myocardial blood flow using dipyridamole would enhance collateral development in miniswine with an ameroid- occluded left circumflex coronary artery (LCx). Two days after surgical instrumentation, the animals received dipyridamole (n = 9), diltiazem as an adenosine-independent vasodilator (n = 8), or control vehicle (n = 7) 90 minutes per day, 5 days per week for 8 weeks. At 5 and 8 weeks, transmural blood flow and systolic wall thickening were measured during infusion of dipyridamole, diltiazem, or vehicle. Transmural blood flow increased similarly in the LCx and nonoccluded regions at 30 and 60 minutes during infusion of either vasodilator. Thus, we believe that similar mechanical stimulation resulted from dipyridamole and diltiazem infusion. There was no change in blood flow during administration of the vehicle. Systolic wall thickening in the collateral-dependent region was not altered by infusion of dipyridamole, diltiazem, or vehicle. Therefore, both vasodilators increased blood flow without eliciting ischemia. After 8 weeks of repeated treatment with each pharmacological agent, at least 24 hours after the last drug infusion, near maximal physiological capacity of the coronary collateral vessels was assessed during treadmill running (approximately 240 beats per minute). Transmural myocardial blood flow ratios, expressed as flow in the LCx divided by flow in the nonoccluded region of the left ventricle, were similar at rest for animals treated with dipyridamole (0.90 +/- 0.03), diltiazem (0.97 +/- 0.05), and control vehicle (0.89 +/- 0.02). However, collateral-dependent myocardial blood flow during exercise was greater (P < .05) in the dipyridamole-treated animals (0.78 +/- 0.04) than in either diltiazem-treated (0.63 +/- 0.09) or vehicle-treated (0.62 +/- 0.02) animals. LCx systolic wall thickening at rest was similar in animals treated with dipyridamole (44.4 +/- 6.3%), diltiazem (42.2 +/- 3.0%), and control vehicle (38.1 +/- 2.8%). During exercise, however, myocardial function in the collateral- dependent region was greater (P < .05) in the dipyridamole-treated (39.2 +/- 5.2%) compared with diltiazem-treated (23.9 +/- 4.0%) and vehicle-treated (26.9 +/- 2.9%) animals.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]

				S. A. Thomas, J. A. Fallavollita, G. Suzuki, M. Borgers, and J. M. Canty Jr Dissociation of Regional Adaptations to Ischemia and Global Myolysis in an Accelerated Swine Model of Chronic Hibernating Myocardium Circ. Res., November 15, 2002; 91(10): 970 - 977. [Abstract] [Full Text] [PDF]

				D. Wothe, A. Hohimer, M. Morton, K. Thornburg, G. Giraud, and L. Davis Increased coronary blood flow signals growth of coronary resistance vessels in near-term ovine fetuses Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R295 - R302. [Abstract] [Full Text] [PDF]

				E. Picano and on behalf of the PISA study group Dipyridamole in chronic stable angina pectoris. A randomized, double blind, placebo-controlled, parallel group study Eur. Heart J., October 1, 2001; 22(19): 1785 - 1793. [Abstract] [PDF]

				F. Lombardi and R. Rambaldi Coronary angiogenesis: dipyridamole is back on the stage? Eur. Heart J., July 2, 2001; 22(14): 1151 - 1153. [PDF]

				R Belardinelli, L Belardinelli, and J.C Shryock Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy Eur. Heart J., July 2, 2001; 22(14): 1205 - 1213. [Abstract] [PDF]

				T. Bombardini, E. Picano, and T. Bombardini The Coronary Angiogenetic Effect of Heparin: Experimental Basis and Clinical Evidence Angiology, November 1, 1997; 48(11): 969 - 976. [Abstract] [PDF]

				W. D. Ito, M. Arras, B. Winkler, D. Scholz, J. Schaper, and W. Schaper Monocyte Chemotactic Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion Circ. Res., June 19, 1997; 80(6): 829 - 837. [Abstract] [Full Text]

				E. Picano and C. Michelassi Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis Cardiovasc Res, March 1, 1997; 33(3): 666 - 670. [Abstract] [PDF]

				D. F. Lazarous, M. Scheinowitz, M. Shou, E. Hodge, M. A. S. Rajanayagam, S. Hunsberger, W. G. Robison Jr, J. A. Stiber, R. Correa, S. E. Epstein, et al. Effects of Chronic Systemic Administration of Basic Fibroblast Growth Factor on Collateral Development in the Canine Heart Circulation, January 1, 1995; 91(1): 145 - 153. [Abstract] [Full Text]